[go: up one dir, main page]

RU2005114487A - Терапевтическое лечение - Google Patents

Терапевтическое лечение Download PDF

Info

Publication number
RU2005114487A
RU2005114487A RU2005114487/15A RU2005114487A RU2005114487A RU 2005114487 A RU2005114487 A RU 2005114487A RU 2005114487/15 A RU2005114487/15 A RU 2005114487/15A RU 2005114487 A RU2005114487 A RU 2005114487A RU 2005114487 A RU2005114487 A RU 2005114487A
Authority
RU
Russia
Prior art keywords
cancer
combination
pharmaceutically acceptable
accordance
acceptable salt
Prior art date
Application number
RU2005114487/15A
Other languages
English (en)
Russian (ru)
Inventor
Франсис Томас БОЙЛ (GB)
Франсис Томас Бойл
Джон Оуэн КЕРУЭН (GB)
Джон Оуэн КЕРУЭН
Нил Джеймс ГАЛЛАГЕР (US)
Нил Джеймс ГАЛЛАГЕР
Урсула Джой ХАНКОКС (GB)
Урсула Джой Ханкокс
Эндрью Марк ХЬЮЗ (GB)
Эндрью Марк ХЬЮЗ
Донна ДЖОНСТОУН (GB)
Донна ДЖОНСТОУН
Сайан Томико ТЕЙЛОР (GB)
Сайан Томико ТЕЙЛОР
Дейвид Уилль м ТОНДЖ (GB)
Дейвид Уилльям ТОНДЖ
Original Assignee
Астразенека Аб (Se)
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб (Se), Астразенека Аб filed Critical Астразенека Аб (Se)
Publication of RU2005114487A publication Critical patent/RU2005114487A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2005114487/15A 2002-10-12 2003-10-07 Терапевтическое лечение RU2005114487A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223854.1 2002-10-12
GBGB0223854.1A GB0223854D0 (en) 2002-10-12 2002-10-12 Therapeutic treatment

Publications (1)

Publication Number Publication Date
RU2005114487A true RU2005114487A (ru) 2006-02-10

Family

ID=9945876

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005114487/15A RU2005114487A (ru) 2002-10-12 2003-10-07 Терапевтическое лечение

Country Status (29)

Country Link
US (1) US20060122180A1 (is)
EP (1) EP1553950B1 (is)
JP (1) JP2006510605A (is)
KR (1) KR20050056238A (is)
CN (1) CN100342853C (is)
AR (1) AR041595A1 (is)
AT (1) ATE369136T1 (is)
AU (1) AU2003269259B2 (is)
BR (1) BR0315140A (is)
CA (1) CA2501959A1 (is)
CY (1) CY1107605T1 (is)
DE (1) DE60315490T2 (is)
DK (1) DK1553950T3 (is)
ES (1) ES2289316T3 (is)
GB (1) GB0223854D0 (is)
IS (1) IS2473B (is)
MX (1) MXPA05003808A (is)
MY (1) MY135441A (is)
NO (1) NO20051658L (is)
NZ (1) NZ539137A (is)
PL (1) PL375584A1 (is)
PT (1) PT1553950E (is)
RU (1) RU2005114487A (is)
SA (1) SA04240502B1 (is)
TW (1) TW200412971A (is)
UA (1) UA82492C2 (is)
UY (1) UY28017A1 (is)
WO (1) WO2004035057A1 (is)
ZA (1) ZA200502874B (is)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2412941C2 (ru) * 2006-03-13 2011-02-27 Инсайсив Фармасьютикалз, Инк. Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
EA201000545A1 (ru) * 2007-10-12 2010-10-29 Астразенека Аб Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу
MX2012001562A (es) * 2009-08-10 2013-01-29 Univ Texas Tratamiento de astrocitos-celulas de tumor con inhibidores de receptores de endotelina.
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
MX2020007293A (es) 2018-01-12 2021-01-08 Enb Therapeutics Inc Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
WO2021011925A1 (en) * 2019-07-17 2021-01-21 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
AR126178A1 (es) 2021-06-22 2023-09-27 Alchemedicine Inc Compuesto, antagonista del receptor de endotelina a y composición farmacéutica

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
CN1298396A (zh) * 1998-04-29 2001-06-06 Osi药物公司 N－(乙炔苯氨基)－6,7－双(2－甲氧基乙氧基)－4－喹唑啉胺甲磺酸盐无水物和一水合物
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2412941C2 (ru) * 2006-03-13 2011-02-27 Инсайсив Фармасьютикалз, Инк. Полиморфы натриевой соли n-(4-хлор-3-метил-5-изоксазолил)-2[2-метил-4,5-(метилендиокси)фенилацетил]тиофен-3-сульфонамида

Also Published As

Publication number Publication date
TW200412971A (en) 2004-08-01
GB0223854D0 (en) 2002-11-20
UY28017A1 (es) 2004-04-30
WO2004035057A1 (en) 2004-04-29
IS7825A (is) 2005-04-26
EP1553950B1 (en) 2007-08-08
MY135441A (en) 2008-04-30
ZA200502874B (en) 2006-02-22
ATE369136T1 (de) 2007-08-15
AU2003269259A1 (en) 2004-05-04
CY1107605T1 (el) 2013-03-13
UA82492C2 (uk) 2008-04-25
JP2006510605A (ja) 2006-03-30
ES2289316T3 (es) 2008-02-01
DK1553950T3 (da) 2007-10-15
US20060122180A1 (en) 2006-06-08
DE60315490T2 (de) 2008-05-08
DE60315490D1 (de) 2007-09-20
NZ539137A (en) 2008-01-31
CN100342853C (zh) 2007-10-17
MXPA05003808A (es) 2005-06-08
AU2003269259B2 (en) 2007-03-15
BR0315140A (pt) 2005-08-16
EP1553950A1 (en) 2005-07-20
CN1703224A (zh) 2005-11-30
IS2473B (is) 2008-12-15
NO20051658L (no) 2005-05-06
CA2501959A1 (en) 2004-04-29
PT1553950E (pt) 2007-09-26
PL375584A1 (en) 2005-11-28
AR041595A1 (es) 2005-05-26
HK1078784A1 (en) 2006-03-24
SA04240502B1 (ar) 2008-09-14
KR20050056238A (ko) 2005-06-14

Similar Documents

Publication Publication Date Title
RU2005114487A (ru) Терапевтическое лечение
AU2017329090B2 (en) Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
La Monica et al. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
RU2011119638A (ru) Способ лечения
DK2068880T3 (da) Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
RU2006121337A (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
JP6892381B2 (ja) 多発性骨髄腫を治療するための薬物の組み合わせ
RU98105512A (ru) Применение производных пиримидина для профилактики рака отдельно или в комбинации с другими терапевтическими мероприятиями
RU2010140795A (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТАГОНИСТАМИ c-met И EGFR
TW200522966A (en) Dosing schedule for a novel anticancer agent
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
Awada et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
US6432979B1 (en) Method of treating or inhibiting colonic polyps and colorectal cancer
RU2011122542A (ru) Способ ингибирования рецепторных тирозинкиназ с помощью внеклеточного антагониста и внутриклеточного антагониста
Park et al. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma
RU2005108349A (ru) Терапевтическое применение
EP4093394A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
RU2020134183A (ru) Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
Xu et al. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far
Bennouna et al. Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress
RU2010119922A (ru) Усовершенствованное противоопухолевое лечение
JP2019515010A5 (is)
RU2012123970A (ru) Тивозаниб и темсиролимус в комбинации
Campas et al. BIBW-2992. Dual EGFR/HER2 inhibitor, oncolytic.